Comparative Pharmacology
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus HI COR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus HI COR.
FLUDROCORTISONE ACETATE vs HI-COR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin and leukotriene synthesis.
0.1 mg orally once daily, range 0.05-0.2 mg/day
0.1-0.2 mg/kg intravenously once.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Terminal elimination half-life is 2-4 hours. Clinical context: Short half-life requires frequent dosing for sustained effect; accumulation possible in renal impairment.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Renal excretion of unchanged drug and metabolites accounts for approximately 70-80% of elimination, with biliary/fecal excretion contributing 20-30%.
Category D/X
Category C
Corticosteroid
Corticosteroid